251 related articles for article (PubMed ID: 33522289)
21. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP; Stahl M; Zeidan AM
Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
[TBL] [Abstract][Full Text] [Related]
22. Acute myeloid leukemia transformed to a targetable disease.
Saleh K; Khalifeh-Saleh N; Kourie HR
Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
[TBL] [Abstract][Full Text] [Related]
23. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
24. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Elderly Patients With Acute Myeloid Leukemia.
Thomas X; Le Jeune C
Curr Treat Options Oncol; 2017 Jan; 18(1):2. PubMed ID: 28144802
[TBL] [Abstract][Full Text] [Related]
26. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
27. Resistance to targeted therapies in acute myeloid leukemia.
Mecklenbrauck R; Heuser M
Clin Exp Metastasis; 2023 Feb; 40(1):33-44. PubMed ID: 36318439
[TBL] [Abstract][Full Text] [Related]
28. Myelodysplastic syndromes and acute myeloid leukemias in the elderly.
Mueller BU; Seipel K; Pabst T
Eur J Intern Med; 2018 Dec; 58():28-32. PubMed ID: 30527920
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
[TBL] [Abstract][Full Text] [Related]
30. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
[TBL] [Abstract][Full Text] [Related]
31. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.
Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M
Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602
[TBL] [Abstract][Full Text] [Related]
32. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
Tallman MS
Hematology Am Soc Hematol Educ Program; 2005; ():143-50. PubMed ID: 16304372
[TBL] [Abstract][Full Text] [Related]
33. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
Kell J
Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450
[TBL] [Abstract][Full Text] [Related]
34. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Fenwarth L; Fournier E; Cheok M; Boyer T; Gonzales F; Castaigne S; Boissel N; Lambert J; Dombret H; Preudhomme C; Duployez N
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781546
[TBL] [Abstract][Full Text] [Related]
37. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara F
Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
[TBL] [Abstract][Full Text] [Related]
38. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Larrosa-Garcia M; Baer MR
Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
[TBL] [Abstract][Full Text] [Related]
39. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
40. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
